Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML
← catalyst calendarSponsored by Aptevo Therapeutics (industry) · APVO — their whole pipeline →.
Phase
Phase 1
Status
Withdrawn
Study type
Interventional
Design
Na · None · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Change of strategy
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2025 | estimated | When the study began enrolling |
| Primary completion | Jan 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2021-07-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2021-12-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- AML
Intervention
- Biological: APVO436
Primary outcome
what the primary-completion date above is the date OFSafety - Incidence of Grade 3-4 AEs and SAEs
measured during first 28 to 35 days of treatment
Permalink · APVO's whole pipeline · Catalyst calendar · Every registered study · What changed